Canagliflozin offers modest weight benefits in obese people

12/10/2013 | MedPage Today (free registration)

Non-hyperglycemic obese and overweight patients who took any of three doses of canagliflozin lost more weight and attained modest BMI reductions compared with those in the placebo group, according to a study in the journal Obesity. However, researchers did not observe significant differences in triglycerides or HDL cholesterol between the groups.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL